Data from the EV-302 trial have been published in the NEJM, showing that the combination of EV and pembrolizumab extended OS and PFS vs chemotherapy in patients with urothelial carcinoma. #urology#oncology#blcsm@brady_urology@JCensits
Read more: https://t.co/v5rIfP6RYv
The FDA has approved nivolumab plus cisplatin and gemcitabine for the frontline treatment of patients with unresectable or metastatic urothelial carcinoma. #FDA#urology#oncology#blcsm
Read more: https://t.co/yTucfq7Doi
The friendliest specialty society around! Join us Sunday for @Endo_Society Day at #AUA23 - @young_endosoc luncheon and packed @FocalSociety@SocietySURS meetings. Visit our booth to join the global community of minimally invasive urologists and save the date for #WCET23!
Interesting, that is what we adresses at EAU wit @cgratzke FDA argues AstraZeneca, Merck's Lynparza only works in subset of prostate cancer patients https://t.co/vc4lILLDEU
At the UroExpert summit we'll have inspiring lectures, discussions, and networking opportunities led by @cgratzke
Today we kicked off with the keynote speaker @BertrandTOMBAL talking about therapies for advanced prostate cancer
#prostatecancer#BayerOncology
Good New today; April 3, 2023, the FDA granted accelerated approval to enfortumab vedotin-ejfv (Padcev, Astellas ) with pembrolizumab (Keytruda, Merck) for pts with LA or mets urothelial ca who are ineligible for cis-containing chemotherapy.@CharleneMantia@BladderCancerUS
Bei Bayer sind wir stolz darauf, #Forschung & Innovation in der #Prostatakrebsbehandlung voranzutreiben. Wir freuen uns auf den #UroExpertSummit vom 21.-22. April in Berlin und darauf unsere Leidenschaft für wissenschaftliche Vorträge und interaktive Diskussionen zu teilen.